Sanofi's dengue vaccine is to make its market debut in Mexico, the French drugmaker said on Wednesday, adding that it expects to have filed for market approval in some 20 countries by year-end.
Sanofi Pasteur, the group's vaccines division, said Mexico had approved the preventive treatment, called Dengvaxia, for all four dengue virus serotypes, but only for patients aged 9 to 45 who live in areas where the disease is endemic.
This means the world's first dengue vaccine has no approval yet for use on young children, a population considered to be most at risk, or . . .
This independent news site is supported by subscribers.
Login now, or subscribe today. As a premium subscriber to our independent news site, for as low as .10 cents per day, you'll unlock full news coverage of the events that shape our city, exclusive interviews with local influencers, and in-depth reports that get to the heart of Puerto Vallarta's unique challenges and triumphs, while also learning more about news throughout Mexico that makes a difference. Help us sustain the future of independent journalism in Puerto Vallarta. It's a small market so advertising doesn't make a dent in the costs, but you can help! Subscribe today and become an essential part of the conversation.
